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license (http://creativeed an online survey on the extent of SI/SB in individuals diagnosed with mild cognitive impairment
(MCI) or dementia who were participating in clinical trials.
Methods: Investigators with experience in conducting SI/SB assessments in clinical trial subjects
with MCI or dementia were invited to complete a global 19-item online survey.
Results: A total of 204 evaluable responses were collected with the majority from North America
and Europe (83.4%) and the remainder from Asia, Latin America, and Mideast/Africa. The mean
(SD) number of subjects personally assessed by the respondents in the past year with MCI, mild-
moderate dementia, or severe dementia was 12.8 (26.2), 31.2 (39.6), and 10.1 (34.7), respectively.
The mean number of subjects in each diagnostic group with suicidal ideation (SI), suicidal behavior
(SB), or completed suicide (CS) was on average quite low (0.3 to 1.1 for SI, 0.1 to 0.2 for SB, and 0.0
to 0.2 for CS). Confidence in subject self-reports of SI/SB over different time periods declined with
increasing severity of cognitive impairment and with increasing duration of the recall time period as-
sessed. Of respondents, 56% and 75% had low confidence in self-ratings of SI/SB from subjects with
severe dementia over the past 24 hours and the past week to 1 month, respectively. Ratings of the reli-
ability of information collected on SI/SB also decreased with increasing severity of cognitive impair-
ment. Approximately 70% of respondents rated the reliability of the information they obtained from
all sources (patient, caregiver, and others) for subjects with MCI as high, but only about half (42.0%
to 55.3%) and less than a quarter (17.4% to 24.3%) rated the reliability of information obtained for
subjects with mild to moderate dementia or severe dementia as high, respectively.
Discussion: These results support the usefulness of prospective SI/SB assessments in MCI and mild
dementia, raise questions about the reliability of assessments in moderate dementia, and confirm their
lack of clinical utility in severe dementia. The results highlight the need for development of validated
assessment instruments adapted to the stage of cognitive decline of the patients under study and may
be the most effective in the earliest stages of the disease.
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In August 2012, the Food and Drug administration (FDA)
issued a revised draft guidance requiring the prospective
assessment of suicidal ideation and suicidal behavior (SI/
SB) in clinical studies of drugs being developed for CNS in-
dications [1,2]. The guidance indicated that for CNS drug
trials, prospective monitoring for SI/SB should be done in
all patients in all studies with a few exceptions (such
as studies in severe dementia). The guidance also
recommended the use of the Columbia-Suicide Severity Rat-
ing Scale (C-SSRS) as the preferred instrument for prospec-
tive assessment of SI/SB, while noting that other instruments
could be acceptable if shown to be valid and to reliably map
potential suicide-related events to the Columbia Classifica-
tion Algorithm of Suicide Assessment (C-CASA) [3,4].
In practice, since the emergence of the guidance, the C-
SSRS has been widely used for the assessment of SI/SB in
clinical trials of patients with mild cognitive impairment
(MCI)/pre-dementia, mild or moderate Alzheimer’s disease
(AD), and other dementias, despite the fact that neither it
nor any other SI/SB assessment instrument has been demon-
strated to be reliable and valid when used in patients with de-
mentia.
After the issuance of the FDA guidance, the Alzheimer’s
Association Research Roundtable formed the Task Force on
Suicidal Ideation and Behavior in Persons with Dementia
Spectrum Conditions, comprised of representatives from in-
dustry, academia, advocacy organizations, and regulatory
agencies. (AARR Task Force members: Larry Alphs
(Chair–SIB Task Force), Janssen Alzheimer’s Immuno-
therapy (JAI); Robert Brashear, JAI; Phillip Chappell, Pfizer;
Yeates Conwell, University of Rochester; Sarah DuBrava,
Pfizer; Dean Hartley, Alzheimer’s Association; Ni Aye
Khin, Food and Drug Administration (FDA); Nick Kozauer,
FDA; DavidMiller, Bracket; Rachel Schindler, Pfizer (Chair
of AARR); Eric Siemers, Eli Lilly & Co; Michelle Stewart,
Pfizer; Kristine Yaffe, UCSF.) Key questions and issues
considered by the task force include: the epidemiology of
SI/SB in AD and other dementias; the cause of suicidal idea-
tion in these conditions; the impact of stage and severity of
cognitive impairment on the incidence of SI/SB; what
assessment tools are available and what is their validity
when used in dementia patients; how can new instruments
more sensitive to the stage of illness be developed; how
best to conduct SI/SB assessments in clinical trials of de-
mentia patients to minimize bias and negative impact; and
what is the preferred methodology and approach to the eval-
uation of signal detection of SI/SB in dementia clinical trials
[5].
In recognition of the lack of any published information on
the use of SI/SB tools in dementia clinical trials, the taskforce developed and conducted an online survey of the
assessment of SI/SB in participants enrolled in clinical trials
of AD and other forms of dementia. The goal of the survey
was to obtain information on the extent of SI/SB in cogni-
tively impaired individuals participating in clinical trials
and the challenges and hurdles encountered by investigators
in conducting SI/SB assessments in this patient population.2. Methods
2.1. Survey questionnaire development
A subcommittee of the AARR SI/SB Task Force identi-
fied potential challenges and issues in the conduct of SI/
SB assessments in clinical studies of patients with cognitive
impairment, based on anecdotal reports and discussion with
key stakeholders. Based on this input, a total of 19 items
were developed for inclusion in the survey.
To complete the survey, a person needed to have person-
ally conducted SI/SB assessments during the course of clin-
ical trials; otherwise, the survey was terminated.
Items assessed information related to the demographics,
background, and clinical experience of respondents and
operational aspects of SI/SB assessment; and asked respon-
dents to rate their level of confidence in subject self-reports
of SI/SB and the reliability of the information obtained. Re-
spondents also rated the level of patient and caregiver accep-
tance of SI/SB assessments as well as how helpful
prospective assessments of SI/SB were in identifying pa-
tients at risk. A final open-ended question invited respon-
dents to provide any additional comments, they wished on
the issue of prospective assessment of SI/SB in patients
with MCI or dementia.
The survey was beta-tested by several experts in the field
external to the working group before being finalized and im-
plemented online.2.2. Sample identification
Sites were invited to participate in the survey using lists of
e-mail addresses provided by Bracket, Inc and the Alz-
heimer’s Association. The e-mail list obtained from Bracket,
Inc. was developed from a previous survey sponsored by the
International Society for CNS Clinical Trials and Methodol-
ogy, which identified sites that had participated in clinical
studies of AD or other dementias (approximately 95% of
sites had participated in AD trials) in the last 2 years [6].
The Alzheimer’s Association email list consisted of physi-
cians who are members of the International Society to
Advance Alzheimer’s Research and Treatment.
The survey was sent to 2160 e-mail addresses using the
services of the software company Convio. A letter
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the survey and stated that the site should have only one per-
son complete the survey and that the person completing the
survey should be someonewho had personally conducted SI/
SB assessments during the course of clinical trials. The data
were collected in March 2013 using an online survey instru-
ment, Survey Gizmo.2.3. Data analysis
All available data were included in the initial evaluation.
In cases of multiple responses from the same IP address,
only the last response was used in the final analysis. Contin-
uous variables were summarized using descriptive summary
statistics. Categorical variables were summarized using fre-
quency and percent. Summaries were evaluated for poten-
tially questionable extreme values, and if found,
summarizations were repeated with and without potentially
erroneous data. A qualitative review and categorization of
open-ended text responses were performed.
A copy of the survey can be found in the Supplementary
Material.3. Results
3.1. Overall response rate
A total of 362 responses were collected over the 4-week
period of the survey (for a response rate of 362 of 2160 or
16.8%). When duplicate responses from sites were elimi-
nated (retaining only the last response from each IP address),
there remained a total of 296 responses, each from a unique
site. Respondents who had not personally conducted SI/SB
assessments were excluded from further analysis, leaving a
final evaluable sample of 204 responses.3.2. Characteristics of respondents
By background training, most of the respondents were
psychologists (26.0%), psychiatrists (21.2%), neurologists
(19.6%), or nurses (16.2%). In terms of the role of the re-
spondents at their site, raters comprised most of the respon-
dents (37.3%), followed by principal investigators (26.5%),
sub-investigators (14.7%), and site coordinators (13.7%).
Most of the responses originated from North America
(39.1%) and Western Europe (32.3%), with less representa-
tion from other regions (Eastern Europe 5 12.0%, Asia 5
10.4%, Latin America 5 5.2%, and Mideast/Africa 5
1.0%).3.3. Clinical experience of respondent sites
Overall, sites reported substantial experience in the
conduct of clinical trials in cognitively impaired subjects.
The mean number of trials per site over the past 2 years
was 1.8 trials inMCI (range, 0–40), 5.2 in mild-moderate de-
mentia (range, 0–50), and 1.1 in severe dementia (range,0–50); sites also reported conducting an average of 2.8
studies in other diagnoses over the same time period (range,
0–30). Estimates of the number of subjects studied were also
substantial. The mean number of cognitively impaired sub-
jects studied per site per diagnostic category was 17.5
(range, 0–400) in MCI, 34.6 (range, 0–325) in mild-
moderate AD, and 7.9 (range, 0–300) in severe AD subjects.
Sites reporting the highest number of trials and subjects
studied (.3 standard deviation [SD] from the mean) were
distributed across most of the geographic regions included
in the sample (North America, 8; Western Europe, 8; Asia,
4; Eastern Europe, 1). In some instances, the number of sub-
jects appeared to be disproportionate to the number of clin-
ical trials reported (e.g., a respondent from China reported
having studied 300 subjects with severe AD while partici-
pating in only 1 clinical trial of severe AD). The largest
numbers of studies (40 MCI, 50 mild to moderate AD, and
50 severe AD) were reported by respondents from sites in
China and Korea, reflecting the experience of very large
specialized clinics serving a large population of subjects
with cognitive impairment.
Respondents were asked to provide estimates of the num-
ber of subjects they had personally assessed in the past year
and howmany of those subjects had reported SI or SB or had
died by completed suicide (CS). SI was referred to in the sur-
vey as “suicidal thinking” but was not further defined so
could have included both passive and active suicidal
thoughts. SB was defined as including actual attempts,
aborted, or interrupted attempts, and preparatory acts toward
an imminent attempt [2]. Nonsuicidal self-injurious behav-
iors were excluded. The data are summarized in Table 1.
In patients personally assessed by the respondents in the
past year, the mean (SD) number of patients with SI was 0.3
(1.1) in MCI, 1.1 (3.2) in mild-moderate dementia, and 0.5
(2.4) in severe dementia. The mean (SD) number of patients
with SB was 0.1 (0.7) in MCI, 0.2 (0.6) in mild-moderate de-
mentia, and 0.1 (0.8) in severe dementia. One CS was re-
ported in a total of 2307 MCI patients, 3 CSs in a total of
5584 patients with mild-moderate dementia, and none in a
total of 1780 patients with severe dementia.3.4. Operational aspects of SI/SB interviews
Most of the respondents reported interviewing both the
subject and the caregiver in performing the SI/SB assess-
ment (68.7% of respondents in MCI, 89.0% in mild-
moderate AD, and 75.0% in severe AD). In the case of
MCI, 30.6% of respondents only interviewed the subject,
whereas 18.1% of respondents only interviewed the subject
in the case of subjects with severe AD.
Among respondents who interviewed both the subject
and the caregiver (N 5 101 to 136), the majority indicated
that discrepancies between the subject and caregiver reports
occurred never or only occasionally in subjects with MCI
(69.3%) or mild to moderate AD (70.1%). About half of
the respondents (47.2%) reported that subject and caregiver
Table 1
Summary statistics for subjects personally assessed by survey respondent in the past year*
Statistic Number assessed Number with SI Number with SB Completed suicides
MCI Mean (SD) 12.8 (26.2) 0.3 (1.1) 0.1 (0.7) 0.005 (0.1)
Median 1 0 0 0
25th, 75th percentiles (0, 15) (0, 0) (0, 0) (0, 0)
Min–Max 0–200 0–10 0–4 0–1
Total 2307 58 29 1
Mild/mod dementiay Mean (SD) 31.2 (49.6) 1.1 (3.2) 0.2 (0.6) 0.02 (0.1)
Median 18 0 0 0
25th, 75th percentiles (8, 35) (0, 1) (0, 0) (0, 0)
Min–Max 0–500 0–25 0–5 0–1
Total 5584 203 27 3
Severe dementia Mean (SD) 10.1 (34.7) 0.5 (2.4) 0.1 (0.8) 0
Median 0 0 0 0
25th, 75th percentiles (0, 5) (0, 0) (0, 0) (0, 0)
Min–Max 0–300 0–20 0–10 0
Total 1780 83 16 0
*Number of survey responses per item ranged from 177–182.
yExcludes as a probable reporting error, one respondent who reported six completed suicides in 30 assessed mild-moderate AD subjects.
Fig. 1. Level of confidence in accuracy of patient self-reports of suicidal
ideation.
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vere dementia. Depending on the diagnostic group, discrep-
ancies between subject and caregiver were reported as
occurring often or always by about 8% to 13% of respon-
dents. In addition, the proportion of respondents reporting
that they were unable to assess if discrepancies existed
ranged from 23.7% for MCI and 15.8% for mild/moderate
dementia to 42.5% for severe dementia. These results high-
light the need for better guidance for clinicians on how
discrepant information should be incorporated into the SI/
SB assessment.
The time required to complete prospective SI/SB assess-
ments did not appear to vary with level of cognitive impair-
ment. About half of the respondents (51.0%–59.9%)
indicated that the prospective assessment of SI/SB could
be done in 15 minutes regardless of the level of impair-
ment, whereas about a third (25.9% in MCI, 34.6% in mild
to moderate AD, and 31.7% in severe AD) indicated that
the interviews required between 15 and 30 minutes to
conduct.
Other sources of data used by respondents included med-
ical or psychiatric records (77.3%), information provided by
the referring physician (59.6%), or information from assis-
ted living or nursing home staff (50.4%). About 13% of re-
spondents indicated that they did not use any source of
information other than the subject and the caregiver.
A total of 37 respondents indicated their site used self-
report questionnaires to evaluate SI/SB in clinical trials of
subjects with MCI or dementia. The most common “self-
report” instrument was the C-SSRS, suggesting the online
self-rated version of the C-SSRS (the “eC-SSRS”) [7] or
perhaps that the respondents did not understand the question.
Other self-report instruments included the Geriatric Depres-
sion Scale [8], the Beck Depression Scale [9], the Beck Sui-
cide Intent Scale [10], the Neuropsychiatric Inventory [11],
and the Sheehan-Suicide Tracking Scale [12].3.5. Qualitative ratings of the level of confidence in and
reliability of SI/SB data from subjects with dementia
In general, the level of confidence respondents had in the
data attained from prospective SI/SB assessments, and their
judgment of the reliability of the data was very similar for
both SI and SB; therefore, results for suicidal ideation and
behavior are discussed together.
Respondents’ level of confidence declined almost mono-
tonically with increasing severity of cognitive impairment
and with increasing duration of the time period over which
subjects were asked to provide information (Figs. 1 and 2).
For example, about 70% of respondents had a high level of
confidence in the accuracy of reports of SI/SB from
subjects with MCI over the past 24 hours. However, less
than half of respondents (22%–38%) had high confidence
Fig. 2. Level of confidence in accuracy of patient self-reports of suicidal
behavior. *Includes actual attempts, aborted or interrupted attempts, and
preparatory acts toward making an attempt (such as acquiring the means
of committing suicide); does not include nonsuicidal self-injurious
behaviors.
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the same time period, and only 12%–15%, in reports from
subjects with severe dementia. The proportion of
respondents with high confidence in the accuracy of
subjects’ reports of SI/SB also decreased with increasing
duration of the recall period, for example, falling to 46%–
51%, 17%, and 6%–9%, for reports covering the past
period ranging from .1 week to 1 month for subjects
with MCI, mild-moderate dementia, and severe dementia,
respectively. It is interesting to note that respondents’ confi-
dence in the accuracy of patient self-reports of SI and SB
was very similar, suggesting investigators do not perceive
any difference in patients’ ability to recollect and report on
past objective behaviors versus past subjective states.
Conversely, the proportion of respondents reporting low
confidence in subject’s reports of past SI/SB increased
with increasing severity of cognitive impairment and
increasing duration of the recall period. In the case of self-
reports from subjects with severe dementia covering the
past week to 1 month period, three-fourths of respondents
indicated that they had a low level of confidence in the accu-
racy of the reports, either for SI or SB.Table 2
Respondent ratings of the reliability of information on SI/SB obtained from all so
MCI (N 5 146) Mild/mo
SI SB SI
Low 6 (4.1%) 8 (5.5%) 12 (8.0%
Medium 32 (21.9%) 24 (16.4%) 68 (45.3%
High 100 (68.5%) 104 (71.2%) 63 (42.0%
Not sure 8 (5.5%) 10 (6.9%) 7 (4.7%
Abbreviations: SI, suicidal ideation; SB, suicidal behavior.Respondent ratings of the reliability (low, medium,
high, not sure) of information on SI/SB obtained from
subjects, caregivers, and others in conducting prospective
assessment of subjects with MCI or dementia also
decreased with increasing severity of cognitive impair-
ment (Table 2). Approximately 70% of respondents rated
the reliability of the information they obtained from all
sources for subjects with MCI as high, but only about
half (42.0% to 55.3%) rated the reliability of information
obtained for subjects with mild to moderate dementia as
high, and less than a quarter (17.4% to 24.3%) rated the
reliability of the information obtained on subjects with se-
vere dementia as high. Conversely, 32.6% and 24.3% of
respondents rated the information obtained from all sour-
ces on suicidal ideation (SI) and suicidal behavior (SB),
respectively, in subjects with severe dementia as having
low reliability, and about a quarter of respondents
(22.9% for SI and 23.6% for SB) indicated that were
not sure how reliable information on this subject group
was.
As shown in Table 2, the proportion of high ratings for the
reliability of information on past suicidal behavior was
somewhat greater than the proportion of high ratings for reli-
ability of information on past suicidal ideation.3.6. Assessment of understanding of the concept of
intention
As shown in Table 3, more than 90% of respondents felt
that subjects with MCI or mild to moderate dementia would
understand the question “Have you had some intention of
acting on your thoughts to kill yourself?” either very much
or to some degree, compared with 36.8% of respondents
for subjects with severe dementia. The proportion of very
much ratings drops off precipitously with increasing severity
of dementia, whereas the proportion of not at all or not sure
ratings is markedly increased in severe dementia.3.7. Subject/caregiver acceptance and clinical usefulness
of prospective assessments of SI/SB
Most respondents rated the level of subject and/or care-
giver acceptance of prospective assessments of SI/SB in
clinical trials as either high or medium (86.9% in MCI,
85.4% in mild to moderate dementia, and 75% in severeurces used in prospective assessments
derate dementia (N5 150) Severe dementia (N 5 144)
SB SI SB
) 12 (8.0%) 47 (32.6%) 34 (24.3%)
) 48 (32.0%) 39 (27.1%) 41 (28.5%)
) 83 (55.3%) 25 (17.4%) 35 (24.3%)
) 7 (4.7%) 33 (22.9%) 34 (23.6%)
Table 3
In your experience, how well can subjects with dementia or Mild Cognitive
Impairment understand what is meant by the statement “Have you had some
intention of acting on your thoughts to kill yourself?”
Level of
understanding
MCI
(N 5 146)
Mild/moderate
dementia
(N 5 150)
Severe
dementia
(N 5 144)
Not at all 4 (2.7%) 6 (4.0%) 71 (49.3%)
To some degree 17 (11.6%) 85 (56.7%) 46 (31.9%)
Very much 118 (80.8%) 54 (36.0%) 7 (4.9%)
Not sure 7 (4.8%) 5 (3.3%) 20 (14.0%)
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sponses increased with increasing severity of cognitive
impairment (13% in MCI, 14.7% in mild to moderate de-
mentia, and 23.6% in severe dementia).
Most of the respondents indicated that prospective assess-
ment of SI/SB was very or moderately helpful in identifying
subjects at risk with MCI (71.8%) or mild to moderate de-
mentia (64.1%), but less than half of respondents (39.4%)
found them equally helpful in subjects with severe dementia.
The proportion of respondents indicating that prospective
assessments were only a little bit or not at all helpful
increased with increasing severity of cognitive impairment,
from 21.8% in MCI, to 29.6% in mild to moderate dementia
and to 45.8% in severe dementia. The proportion of respon-
dents rating prospective assessments as not at all helpful rose
from 3.5% in MCI and 4.2% in mild to severe dementia to
19.7% in severe dementia; and 14.8% of respondents indi-
cated that they had no opinion of the helpfulness of assess-
ments in patients with severe dementia.Table 4
Thematic categorization of responses to open-ended question
Category N Example
Not necessary or useful 5 In my opinion and ex
necessary to check
and mild cognitive
Negative comment about C-SSRS 4 In my professional op
population.
Important to assess/valuable 4 I think it is very impor
and it can help us t
important
Important to use caregiver and patient input 3 Best judged by clinici
Have had reports of suicidal ideation/behavior 2 Of my.3000 cogniti
screened 1 for SI,
Language/translation problems 1 It is a problem to pres
personally would n
although I fell [sic]
Conduct at every visit 1 We use sponsor-provi
High-functioning patients are offended 1 Some higher functioni
actions, and so fort
Assessment at every visit is too frequent 1 Despite limitations, in
have a problem wit
on a regular basis (
Patients deny SI/SB/never had positive report 1 All the subjects that I
[anticipatory] of su
Other (unable to classify above) 33.8. Responses to open-ended question
The final question allowed respondents to write any addi-
tional comments they had. Major topics included comments
on the usefulness of SI/SB assessments in patients with
cognitive impairment, the limitations of specific scales
(e.g., the C-SSRS), the benefits of doing SI/SB assessments,
the importance of obtaining input from both caregivers and
patients, and the low incidence of SI/SB in patients with
dementia (Table 4).4. Discussion
The results of this survey provide preliminary evidence
that SI/SB does occur in patients participating in clinical tri-
als of dementia spectrum disorders; yet, the overall inci-
dence of SI/SB in clinical studies of patients with
dementia appears likely to be quite low. However, the accu-
racy and reliability of SI/SB assessments in this patient pop-
ulation appear to be directly impacted by the level of
cognitive impairment, such that meaningful assessment of
suicidal risk and intent over even a recent period of time
may not be practicable in patients with more severe cogni-
tive impairment. Nonetheless, consistent with one of the
chief aims of the draft FDA guidance—to ensure patient
safety [1,2]—most of the survey respondents found
prospective SI/SB assessments helpful in identifying
patients at risk who had MCI or mild to moderate
dementia, although not patients with severe dementia.
These data, taken with the lack of validated assessment
instruments adapted to the stage of cognitive decline,perience, the risk of suicide is very low in this patient population. It is not
this kind of behavioral (sic). I have treated for many years Alzheimer disease
impaired patients, and I have never had a case.
inion, C-SSRS is not an appropriate measuring tool for most of our patient
tant and does not require too much time to evaluate suicidal risk in dementia,
o detect some problems not always identified by caregivers and patients as
an with interview of both and independent assessment.
vely impaired patients in my practice, there were exactly two who have ever
and they were women who had a Hx: SI/SA much earlier in their lives.
ent this survey in English to, for example, German native speaker as I am. I
ot rely on information based on surveys like this in foreign languages
my English is not that bad!
ded suicidality assessment forms for the assessor to complete at each visit.
ng patients are very offended when asking questions about suicidal thoughts,
h
clusion of the assessment at least allows the topic to be discussed openly. I do
h the frequency of the assessment, especially is [sic] subjects who at the site
i.e., monthly) and have adequate opportunity
have evaluated in my site recount not to have ideas anticipatorias
icide.
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SI/SB in dementia patients.
The survey respondents reported substantial experience
in conducting clinical trials and prospective assessment of
SI/SB in cognitively impaired subjects. Nonetheless, the
number of subjects personally assessed by the respondents
in the past year who had SI, SB, or CS was on average
quite low (Table 1). The apparent low levels of SB and
CS reported in patients with more severe dementia seem
consistent with the expectation that increasing cognitive
impairment along with increased overall disability and
dependency is likely to lead to reduced opportunity and
capacity to plan for and execute self-harmful behaviors.
On the other hand, the apparent higher rate of SI reported
in severe dementia relative to mild-moderate dementia
and MCI seems counter to respondents’ reports of the
increased difficulty of obtaining accurate and reliable
self-reports of SI in patients with severe dementia and
the increased reliance on caregiver input for assessment
of more severely impaired patients (which may be
confounded by bias or projection). In patients with more
severe impairment, where assessments of subjective states
may often be based on inferences from caregivers rather
than observed behaviors, confounding of passive SI with
active SI also may occur more commonly. Although of in-
terest, these results should be regarded with caution given
the limitations of the survey methodology which relies on
unverified self-report vulnerable to recollection bias and
which did not take into account such factors as the fre-
quency of SIB assessments and the duration of clinical tri-
als, which could impact the rate of detection and reporting
of SI/SB. None the less, future studies, using more
rigorous methodologies, should be conducted to deter-
mine if there is a relationship between severity of cogni-
tive impairment and the risk of SI/SB.
As might be expected, respondents’ confidence in subject
self-reports of SI/SB over different time periods declined
markedly with increasing severity of cognitive impairment
and with increasing duration of the time period over which
subjects were asked to provide information. In addition,
respondents’ ratings of the reliability of the information on
SI/SB collected from all sources (patient, caregiver, and
others) also decreased with increasing severity of cognitive
impairment. The lowest levels of confidence and reliability
were assigned to SI/SB patients with severe dementia. How-
ever, a substantial minority of respondents (16% to 43%
depending on the past time period) also had low confidence
in self-reports of SI/SB obtained from patients with mild to
moderate dementia and rated the reliability of assessments in
this patient group as low or medium (53.3% for SI, 40.0% for
SB). Interestingly, 30% to 50% of respondents also had low
or moderate confidence in self reports of SI/SB from patients
with MCI. Given the mild degree of cognitive impairment in
patients with MCI, this lack of confidence may also reflect
the difficulty many patients may have in speaking about their
suicidal ideas and impulses [8].These results raise questions about the validity and reli-
ability of SI/SB assessments in patients withmild tomoderate
as well as severe cognitive impairment and highlight the need
for rigorous studies of the psychometric performance of the
scales being used in this patient population. Further study of
SI/SB assessment tools in this population is needed to identify
existing tools or develop new ones capable of more robust SI/
SB detection [5]. Given the results of this survey, taken with
the variability in individual rates of cognitive decline [13],
the threshold of cognitive impairment beyond which reliable
assessments of SI/SB is no longer possible may be more a
gray zone rather than a sharp line separating mild-moderate
and severe dementia.
Operational challenges did not appear to be a major
concern for the survey respondents. The majority reported
that patients and caregivers are generally accepting of SI/SB
assessments and that most assessments could be completed
within 15 minutes, regardless of the severity level of the pa-
tient’s dementia. The most notable challenges reported by
the respondents related to assessment of patients with severe
dementia. Among respondents who routinely interview both
the patient and caregiver, nearly half indicated they could
not assess whether there were discrepancies between the sub-
ject and caregiver reports they obtained, and about a quarter of
respondents indicated they were not sure how reliable infor-
mation onSI/SBobtained fromall sources for patientswith se-
vere dementia was. These results indicate such discrepancies
are not uncommon and, although the survey did not ask how
these were resolved, may highlight the need for instruments
to provide better guidance for clinicians on how discrepant in-
formation should be incorporated into the SI/SB assessment.
Some of the open-ended commentswere positive in nature,
highlighting the benefits to patient safety. Other respondents
commented that they had seldom or never encountered SI/
SB in their clinical practice with dementia patients and ques-
tioned the necessity or usefulness of doing SI/SB assessments
in clinical trials of patients with dementia. Additionally,
several respondents raised concerns about the appropriateness
of using the C-SSRS in patients with dementia.5. Limitations of the study
Limitations of this study include the low response rate
and the reliance on unverified self-report that is inherent to
the survey methodology. There is evidence that the response
rates of clinicians to surveys of all types, including elec-
tronic surveys, are diminishing [14]. Hence, low response
rates are a common liability of Internet surveys and may
lead to nonresponse bias that may limit the generalizability
of the findings.
An additional limitation of the study is the lack of items
inquiring about specific SI/SB rating scales. Other than
one item asking about the use of patient self-report mea-
sures, there were no questions about site experience with
specific SI/SB assessment instruments. However, it is a
P. Chappell et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 60-68 67reasonable assumption that most sites are using the C-SSRS,
as recommended in the FDA guidance.
The survey also did not inquire about the presence and po-
tential contribution of comorbid psychiatric conditions.
Depression, in particular, is a well-established risk factor
for suicide, which is very prevalent among elderly patients
with cognitive impairment [5,15–17] and which can
confound attempts to elucidate the unique contribution of
underlying dementia to the risk of suicide [18,19].
Although the objective of the survey, as presented to the
respondents and as reflected in the survey title, was to
inquire about site experiences in prospective assessment of
SI/SB in clinical trials of patients with dementia or MCI, it
is possible that past (pre-trial) SI/SB may have been
confounded with new onset SI/SB, occurring during the
clinical study.
The survey also does not address whether respondent re-
ports differed based on differences in methodology used to
assess SI/SB (i.e., some respondents only interviewed the
subject, whereas others interviewed both the subject and
the caregiver, interviews varied in length) or on differences
in the training and educational background of the respon-
dents (i.e., 45% of respondents were physicians, 44% psy-
chologists, nurses, or social workers, and 11% study
coordinators and raters without professional degrees).
Finally, although most respondents reported that SI/SB
assessments were helpful in identifying subjects at risk
(i.e., 71.8% in MCI, 64.1% in mild-moderate dementia,
and 39.4% in severe dementia), the survey did not explore
whether detecting SI/SB actually improved patient out-
comes. Given the significant effort now mandated by the
FDA to conduct prospective assessments of SI/SB in clinical
trials of patients with MCI and dementia, this is an important
question that needs to be addressed in future studies.6. Conclusions
Despite the limitations of this survey, these data indicate
that suicidal ideation and behavior do occur in clinical trials
of patients with MCI or dementia. However, the reported
occurrence of SB and CS appears to be lower than SI and
may decline further with increasing severity of dementia.
The occurrence of SI/SB in clinical trials of dementia should
not be surprising given reports on the background incidence
of SI/SB in elderly and dementia patients [12,20–24].
Studies of the prevalence of SI/SB in patients with
dementia in settings other than clinical trials have shown
highly variable results (ranging from 1% to .42%) due to
methodologic differences, the failure to use standardized
terminology, and the lack of well-validated tools for
assessment of SI/SB in this patient population (reviewed in
[5]). As far as the authors are aware, there are no published
data on the incidence of SI/SB in patients in clinical trials of
dementia.
The survey results support the usefulness of prospective
assessment of SI/SB in clinical trials involving MCI andmilder forms of dementia, raise important questions about
the validity and reliability of SI/SB assessments in moder-
ately severe dementia, and confirm that assessment of SI/
SB in severe dementia is not likely to be clinically useful.
More than anything, the data highlight the need for rigorous
studies of the psychometric properties of the currently avail-
able assessment tools across the full range of cognitively
impaired patients and the need for development of validated
assessment instruments and methods of assessment adapted
to the stage of cognitive decline of the patients under study.
As suggested by this survey, improvements in the field will
require addressing a host of issues which we have discussed
in more detail in a companion review on assessing SI/SB in
adults with cognitive decline and dementia [5].
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.trci.2016.02.002.RESEARCH IN CONTEXT
1. Systematic review: In recognition of the lack of any
published information on the use of suicide ideation
and suicide behavior (SI/SB) tools in mild-cognitive
impairment and dementia clinical trials, the Alz-
heimer’s Association convened a task force to assess
these issues and conducted an online survey on the
extent of SI/SB in dementia patients participating in
clinical trials. The goal of the survey was to obtain
information which has not been previously assessed
on the extent of SI/SB in cognitively impaired in-
dividuals participating in clinical trials.
2. Interpretation: The novel data presented here support
the usefulness of prospective SI/SB assessments in
MCI and mild dementia in clinical trials, raise ques-
tions about the reliability of assessments in moderate
dementia, and confirm their lack of clinical utility in
severe dementia.
3. Future directions: The results highlight the need for
development of validated assessment instruments
adapted to the stage of cognitive decline of the pa-
tients under study.References
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